Clinical Trials in Barranquilla, Atlántico
13 recruiting
Showing 1–12 of 12 trials
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled204 locationsNCT06422143
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled250 locationsNCT06841354
Recruiting
Phase 2Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart FailureLeft Ventricular Systolic Dysfunction
Merck Sharp & Dohme LLC342 enrolled102 locationsNCT05714085
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled274 locationsNCT06925737
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 1Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled66 locationsNCT06395103
Recruiting
Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled70 locationsNCT07044297
Recruiting
Phase 2
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Arthritis, Rheumatoid
Merck Sharp & Dohme LLC182 enrolled61 locationsNCT07176390
Recruiting
Not Applicable
Music Therapy and Pre-recorded Music on Patients and Caregivers in the Emergency Unit
StressAnxietyWell-Being, Psychological
Claudia Aristizábal243 enrolled2 locationsNCT06510153